

Innova Lateral Flow SARS-CoV-2 Antigen test accuracy in Liverpool Pilot: Preliminary Data

Marta García-Fiñana, David Hughes, Chris Cheyne, Girvan Burnside, Iain Buchan, Calum Semple at University of Liverpool as part of NHS Cheshire and Merseyside CIPHA (Combined Intelligence for Population Health Action). 25th November 2020

The Liverpool Health Protection Board decided yesterday to pause plans to use Innova Lateral Flow SARS-COV-2 Antigen tests (LFT) in test-to-enable visitor access to care home settings due to the accuracy statistics presented below, derived from data received in the past 24h from DHSC who have been running a Quality Assurance programme.

Aim: To compare the classifications made using military supervised self-administered swabs with LFT made on site, vs those obtained by the same asymptomatic person using a second self-administered swab and assayed by a second LFT and reverse transcribed quantitative polymerase chain reaction (PCR) at a DHSC designated quality assurance (QA) laboratory and then investigate the association between LFT prediction and cycle threshold (Ct) values from a PCR test.

Ct number is inversely correlated with virus specific nucleic acid level in the sample, a surrogate marker of viral load.

Table 1: Comparison of LFT Site Results and LFT QA Results

| | | LFT Site Result | | |
|---------------|----------|-----------------|----------|------|
| | | Negative | Positive | Void |
| LFT QA Result | Negative | 3164 | 1 | 1 |
| | Positive | 0 | 25 | 0 |
| | Void | 0 | 0 | 8 |

There are paired data for **3199 patients**. A comparison of the LFT site results to the QA PCR results is shown in Table 2.

Table 2: Comparison of LFT Site Results and PCR Results

| | | PCR QA Result | | |
|-----------------|----------|---------------|----------|------|
| | | Negative | Positive | Void |
| LFT Site Result | Negative | 2979 | 23 | 162 |
| | Positive | 2 | 22 | 2 |
| | Void | 8 | 1 | 0 |

Accuracy measures (excluding VOID results), assuming PCR is gold standard: -

Including 95% confidence intervals: -

Sensitivity (true positive rate)

0.488889 (0.337034 to 0.64226), **48.89% (33.7% to 64.23%)**

Specificity (true negative rate)

0.999329 (0.997579 to 0.999919), **99.93% (99.76% to 99.99%)**

Predictive value of +ve test (post-test likelihood of disease)

0.916667 (0.730027 to 0.989744), **91.67% (73% to 98.97%), change = 91%**

Predictive values of -ve test (post-test likelihood of no disease)

0.992338 (0.988526 to 0.995137), **99.23% (98.85% to 99.51%), change = 0%**

(post-test disease likelihood despite -ve test)

0.007662 (0.004863 to 0.011474), 0.77% (0.49% to 1.15%), change = 0%

We compared the site LFT test result to the Ct value from the QA PCR test. This was calculated as the average of existing values for “N_gene”, “S_gene” and “ORF lab”

Table 3: Comparison of LFT Site Results and QA PCR Ct values for positive PCR samples.

| | | Ct score from PCR test | | | | Negatives | Void |
|---------------------------------|----------|------------------------|------------------------|------------------------|------------------------|-----------|------|
| | | <20 | 20-25 | 25-30 | 30-35 | | |
| LFT Site Results | Negative | 2 | 7 | 6 | 8 | 2979 | 162 |
| | Positive | 12 | 8 | 1 | 1 | 2 | 2 |
| | Void | 1 | 0 | 0 | 0 | 8 | 0 |
| Cumulative Sensitivity (95% CI) | | 85.7 (57.2 to 98.2) | 69.0 (49.2 to 84.7) | 58.3 (40.8 to 74.5) | 48.9 (33.7 to 64.2) | | |




Figure 1: Number of samples (positive and negative by LFT) according to Ct value. Cumulative proportions and 95% CI are also displayed.

END